Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
4.800
+0.150 (3.23%)
At close: Mar 6, 2026, 4:00 PM EST
4.509
-0.291 (-6.07%)
After-hours: Mar 6, 2026, 6:25 PM EST
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$4,230,833
Market Cap
288.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AC Immune | 172 |
| Puma Biotechnology | 172 |
| Coherus Oncology | 158 |
| Cabaletta Bio | 151 |
| Silence Therapeutics | 116 |
| OmniAb | 114 |
| C4 Therapeutics | 110 |
| Enlivex | 71 |
ALDX News
- 17 days ago - Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
- 2 months ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript - Seeking Alpha
- 2 months ago - Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease - Business Wire
- 4 months ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript - Seeking Alpha
- 4 months ago - Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast - Business Wire
- 4 months ago - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 4 months ago - Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET - Business Wire